Serial 18F-choline-PET imaging in patients receiving enzalutamide for metastatic castration-resistant prostate cancer: response assessment and imaging biomarkers

被引：29
作者：
Maines, Francesca [1 ]
Caffo, Orazio [1 ]
Donner, Davide [2 ]
Sperduti, Isabella [3 ]
Bria, Emilio [4 ]
Veccia, Antonello [1 ]
Chierichetti, Franca [2 ]
Tortora, Giampaolo [4 ]
Galligioni, Enzo [1 ]
机构：
[1] Santa Chiara Hosp, Med Oncol, Largo Med Doro 1, I-38100 Trento, Italy
[2] Santa Chiara Hosp, Nucl Med, Largo Med Doro 1, I-38100 Trento, Italy
[3] Regina Elena Inst Canc Res, Biostat, Rome, Italy
[4] Univ Verona, Azienda Osped Univ Integrata, Med Oncol, P Le LA Scuro 10, I-37134 Verona, Italy
来源：
FUTURE ONCOLOGY | 2016年 / 12卷 / 03期
关键词：
F-18-choline PET; castration-resistant prostate cancer; enzalutamide; response; POSITRON-EMISSION-TOMOGRAPHY; RENAL-CELL CARCINOMA; SOLID TUMORS; INCREASED SURVIVAL; TARGETED THERAPY; PET/CT; CRITERIA; CHEMOTHERAPY; ABIRATERONE; RECIST;
D O I：
10.2217/fon.15.277
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Aim: High rate of non-target lesions in metastatic castration-resistant prostate cancer usually limits applicability of Response Evaluation Criteria in Solid Tumors (RECIST) criteria, and this has led to a growing interest in using PET/computed tomography (CT). We prospectively investigated the role of F-18-choline (FCH)-PET/CT in patients receiving enzalutamide after docetaxel. Patients & methods: 30 patients were monitored by means of FCH-PET/CT before and during the treatment. A Cox proportional hazards regression model was used to assess the associations between metabolic parameters and clinical outcomes. Results: Univariate analysis showed no significant correlation between biochemical and FCH-PET responses. Multivariate analysis showed that only baseline maximum standardized uptake value (SUVmax) significantly correlated with biochemical progression-free survival, radiological progression-free survival and overall survival. Conclusion: Our findings suggest that FCH-PET/CT may play a role in defining prognosis of patients receiving enzalutamide because baseline SUVmax proved to be an independent prognostic factor.
引用
收藏
页码：333 / 342
页数：10
相关论文
共 35 条
[1]   [methyl-3H]Choline incorporation into MCF7 tumour cells:: correlation with proliferation [J].
Al-Saeedi, F ;
Welch, AE ;
Smith, TAD .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 (06) :660-667
[2]   18F-fluorocholine for prostate cancer imaging: a systematic review of the literature [J].
Bauman, G. ;
Belhocine, T. ;
Kovacs, M. ;
Ward, A. ;
Beheshti, M. ;
Rachinsky, I. .
PROSTATE CANCER AND PROSTATIC DISEASES, 2012, 15 (01) :45-55
[3]  
Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095
[4]   18F Choline PET/CT in the Preoperative Staging of Prostate Cancer in Patients with Intermediate or High Risk of Extracapsular Disease: A Prospective Study of 130 Patients [J].
Beheshti, Mohsen ;
Imamovic, Larisa ;
Broinger, Gabriele ;
Vali, Reza ;
Waldenberger, Peter ;
Stoiber, Franz ;
Nader, Michael ;
Gruy, Bernhard ;
Janetschek, Guenter ;
Langsteger, Werner .
RADIOLOGY, 2010, 254 (03) :925-933
[5]   In vivo uptake of [11C]choline does not correlate with cell proliferation in human prostate cancer [J].
Breeuwsma, AJ ;
Pruim, J ;
Jongen, MM ;
Suurmeijer, AJ ;
Vaalburg, W ;
Nijman, RJ ;
de Jong, IJ .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 (06) :668-673
[6]   Metastatic patterns of prostate cancer:: An autopsy study of 1,589 patients [J].
Bubendorf, L ;
Schöpfer, A ;
Wagner, U ;
Sauter, G ;
Moch, H ;
Willi, N ;
Gasser, TC ;
Mihatsch, MJ .
HUMAN PATHOLOGY, 2000, 31 (05) :578-583
[7]  
Caroli P, 2015, EUR J NUCL MED MOL I, V42, P1276
[8]   11C-Choline PET/CT Scan in Patients With Prostate Cancer Treated With Intermittent ADT A Sequential PET/CT Study [J].
Ceci, Francesco ;
Schiavina, Riccardo ;
Castellucci, Paolo ;
Brunocilla, Eugenio ;
Fuccio, Chiara ;
Colletti, Patrick M. ;
Ferretti, Alice ;
Chondrogiannis, Sotirios ;
Rubello, Domenico ;
Romagnoli, Daniele ;
Malizia, Claudio ;
Martorana, Giuseppe ;
Fanti, Stefano .
CLINICAL NUCLEAR MEDICINE, 2013, 38 (07) :E279-E282
[9]   Exploring the potential of [11C]choline-PET/CT as a novel imaging biomarker for predicting early treatment response in prostate cancer [J].
Challapalli, Amarnath ;
Barwick, Tara ;
Tomasi, Giampaolo ;
Doherty, Michael O' ;
Contractor, Kaiyumars ;
Stewart, Simon ;
Al-Nahhas, Adil ;
Behan, Kevin ;
Coombes, Charles ;
Aboagye, Eric O. ;
Mangar, Stephen .
NUCLEAR MEDICINE COMMUNICATIONS, 2014, 35 (01) :20-29
[10]   Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria [J].
Choi, Haesun ;
Charnsangavej, Chuslip ;
Faria, Silvana C. ;
Macapinlac, Homer A. ;
Burgess, Michael A. ;
Patel, Shreyaskumar R. ;
Chen, Lei L. ;
Podoloff, Donald A. ;
Benjamin, Robert S. .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (13) :1753-1759
1234